Compare Summit Therapeutics Inc (SMMT) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Waste Management, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.55 (market cap $13.79B), while Waste Management, Inc. trades at $217.1 (market cap $87.05B). The key difference: Waste Management, Inc. is far larger — about 6.3× Summit Therapeutics Inc's market cap, and Waste Management, Inc. pays a 1.74% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WM | |
|---|---|---|
Market Cap | $13.79B | $87.05B |
Sector | Health | Industrials |
52-Week High | $26.38 | $246.51 |
52-Week Low | $12.43 | $196.77 |
Enterprise Value | $13.11B | $109.85B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
WM trades at $217.78, down 0.55% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing Q4 2025. Revenue grew to $25.20B in 2025, with strong profitability margins. Analysts maintain a buy consensus with a $263.43 price target, though technical indicators show near-term pressure.
The outlook is supported by steady waste-service demand and sustainability investments, but high debt levels and valuation concerns pose risks. CEO transition adds uncertainty, while institutional buying signals confidence. Upside exists if execution aligns with analyst targets, but investors should weigh premium valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
